VII

FDA Approves First Topical Gene Therapy for Treatment of Wounds in Patients with Dystrophic Epidermolysis Bullosa

Retrieved on: 
Friday, May 19, 2023
COL7, COL7A1, DEB, Dermis, Chills, RDEB, Connective tissue, Food, Center for Biologics Evaluation and Research, Epidermis, Nail, Concha bullosa, Cough, Trial of the century, Rash, Hydrogen peroxide, VII, Genetic disorder, Patient, Paratriathlon, Research, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Red, Skin, Caregiver, Safety, Wound healing, Vaccine, Birth control, Nursing

This gene encodes type VII collagen (COL7), which is an essential protein that helps strengthen and stabilize the outer and middle layers of the skin.

Key Points: 
  • This gene encodes type VII collagen (COL7), which is an essential protein that helps strengthen and stabilize the outer and middle layers of the skin.
  • When COL7A1 is deficient, skin layers can separate, causing painful and debilitating blisters and wounds.
  • DEB usually presents itself at birth and is divided into two major types depending on the inheritance pattern: recessive dystrophic epidermolysis bullosa (RDEB) and dominant dystrophic epidermolysis bullosa (DDEB).
  • Vyjuvek is a genetically modified (engineered in a laboratory) herpes-simplex virus used to deliver normal copies of the COL7A1 gene to the wounds.

Abeona Therapeutics Announces Additional Phase 3 VIITAL™ Study Results for EB-101 Presented at the International Societies for Investigative Dermatology 2023 Meeting

Retrieved on: 
Thursday, May 11, 2023
ISID, RDEB, Quality of life, Concha bullosa, Blister, Stanford University School of Medicine, VII, International Society for Infectious Diseases, Itch, Principal, Wound healing, Dermatology

CLEVELAND, May 11, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced an oral presentation of additional data from the Company's pivotal Phase 3 VIITAL™ study evaluating its investigational EB-101 for recessive dystrophic epidermolysis bullosa (RDEB).

Key Points: 
  • CLEVELAND, May 11, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced an oral presentation of additional data from the Company's pivotal Phase 3 VIITAL™ study evaluating its investigational EB-101 for recessive dystrophic epidermolysis bullosa (RDEB).
  • The data presentation occurred earlier today during the inaugural International Societies for Investigative Dermatology (ISID) Meeting in Tokyo, Japan.
  • In addition to significantly reducing pain, patient-reported outcomes related to itch and blistering showed significantly greater improvement with EB-101 treatment.
  • EB-101 was shown to be well-tolerated with no serious treatment-related adverse events observed, consistent with past clinical experience.

AM Best Upgrades Credit Ratings of Foresight's Carrier MS Transverse to A (Excellent)

Retrieved on: 
Wednesday, May 10, 2023
Insurance, Business development, Risk management, AM Best, Foresight, VII, MGA, MS&AD Insurance Group, Credit, SAN, Cryptocurrency

SAN FRANCISCO, May 10, 2023 /PRNewswire/ -- Foresight Commercial Insurance , the workers' compensation provider that reduces claims frequency with proprietary safety technology, today announced that its carrier, MS Transverse Insurance Group , received upgraded credit ratings by AM Best and now holds "A" (Excellent) in both Financial Strength and Long-Term Issuer Credit Ratings.

Key Points: 
  • SAN FRANCISCO, May 10, 2023 /PRNewswire/ -- Foresight Commercial Insurance , the workers' compensation provider that reduces claims frequency with proprietary safety technology, today announced that its carrier, MS Transverse Insurance Group , received upgraded credit ratings by AM Best and now holds "A" (Excellent) in both Financial Strength and Long-Term Issuer Credit Ratings.
  • In March 2022, MS Transverse's reserves rating was upgraded from A- VII to A- VIII (seven to eight).
  • "We are pleased that AM Best has recognized our progress towards building the preeminent solution for MGAs, Program Managers, and their clients.
  • Our new involvement with MS&AD Insurance Group bodes well for us to continue this journey," said Ric Victores, MS Transverse Head of Business Development.

RGA Completes Transfer of HLAC to Omnilife Insurance Company Limited

Retrieved on: 
Tuesday, May 9, 2023
Professional Services, Business, Health, Insurance, Health Insurance, Finance, Financial services, Part, Marketing, VII, Acquisition, Reinsurance Group of America, RGA, NYSE, Grupo Omnilife

Reinsurance Group of America, Incorporated (NYSE: RGA) a leading global life and health reinsurer, today announced it has completed the transformation of the Hodge Life Assurance Company Limited (HLAC) business that RGA purchased in July 2021.

Key Points: 
  • Reinsurance Group of America, Incorporated (NYSE: RGA) a leading global life and health reinsurer, today announced it has completed the transformation of the Hodge Life Assurance Company Limited (HLAC) business that RGA purchased in July 2021.
  • HLAC’s insurance business was transferred to another group company, Omnilife Insurance Company Limited (Omnilife), under a Financial Services and Marketing Act 2000 Part VII transfer.
  • “Providing a seamless experience to our customers has been a key priority underpinning the Part VII transfer,” said Deian Jones, CEO, Omnilife and HLAC.
  • “We are very pleased to welcome the HLAC policyholders to Omnilife.”
    No liabilities remain in HLAC, and the company will therefore be deauthorized.

Akuo and Atlantica Sustainable Infrastructure Announce the Financial Close and the Start of Construction of a 80 MWp Solar PV Portfolio in Chile

Retrieved on: 
Thursday, May 4, 2023
Engineering, procurement, and construction, Senior, XVI, Engineering, Construction, Electricity, IX, GHG, Climate change, DNB, Yale Program on Climate Change Communication, Government, Plant, Atlantica, VII, Investment, VIII, Communication, Growth, Integration, CO2, Renewable energy, LATAM

Once commissioned, the portfolio will deliver enough electricity to power close to 60,000 households.

Key Points: 
  • Once commissioned, the portfolio will deliver enough electricity to power close to 60,000 households.
  • These nine solar farms will help the country to diversify its electricity mix which currently depends heavily on fossil fuels.
  • Akuo and Atlantica Sustainable Infrastructure are the equity sponsors whereby the debt financing is provided by DNB.
  • Martin Bocage, Akuo Country Manager for Chile, Argentina and Uruguay says: “Akuo is a committed stakeholder to Chile’s energy transition and we stick to our words.

Greycroft Closes On More Than $1 Billion To Back the Next Generation of Category-Defining Companies

Retrieved on: 
Wednesday, April 26, 2023
Banking, Professional Services, Finance, The Carlyle Group, Culture, Intelligence, Partner (business rank), Icertis, VII, Investment, Entrepreneurship, Renewable energy, Flutterwave, Greycroft

Greycroft, a seed-to-growth venture capital firm investing in entrepreneurs who build category-defining companies, today announced the closing of more than $1 billion of capital commitments across new funds.

Key Points: 
  • Greycroft, a seed-to-growth venture capital firm investing in entrepreneurs who build category-defining companies, today announced the closing of more than $1 billion of capital commitments across new funds.
  • “We are witnessing a once-in-a-generation industrial transformation driven by advancements in artificial intelligence and the increasing need for sustainable products.
  • Greycroft has a consistent track record of identifying and investing in innovative companies in sectors like consumer Internet, enterprise software, financial services, and healthcare.
  • Greycroft targets investments from $500K up to $50 million in early-stage and high-growth companies worldwide, with investments in 32 states across the U.S and 17 countries.

Allianz Trade expands its Excess of Loss (XoL) reach with additional resources in Germany and Singapore, and new teams in Spain and Brazil

Retrieved on: 
Tuesday, April 18, 2023
Eduardo Xol, Excess, XI, IX, Multimedia, VII, Allianz, VIII, Disease, Growth, Mortality, III, AA, VI, Risk management, Reinsurance, Insurance, Bank

Allianz Trade is committed to supporting these markets by investing in dedicated teams on the ground.

Key Points: 
  • Allianz Trade is committed to supporting these markets by investing in dedicated teams on the ground.
  • This translates into additional resources in Germany and Singapore, where the company already delivers XoL solutions, and the creation of new XoL teams in Spain and Brazil, thus extending its global presence for this kind of solution.
  • The Excess of Loss solution supports over 300 companies today, protecting their balance sheets against exceptional credit losses.
  • By investing in local teams, we are ensuring our partners have access to Excess of Loss specialists in every region", said Alexia Parmentier, Global Head of Excess of Loss at Allianz Trade.

Hyros Announces AdTech Veteran & Entrepreneur Inman Breaux as Chief Executive Officer to Helm the Leading Multi-Channel Attribution Company

Retrieved on: 
Tuesday, March 28, 2023
Software, Media, Internet, Professional Services, Technology, Digital Marketing, Data Analytics, Online Privacy, Marketing, Audio, Video, Advertising, Communications, Becker, Hilltop Holdings Inc., Breaux, Martech, Multimedia, Privacy, Adtech (company), SMB, Magnite Inc, MoVoxx, VII, Acquisition, Growth, System, ROI, NYSE, Bâtiment des Forces motrices, Management, Cryptocurrency, Hyro the Hero, Inc.

Hyros Inc. (“Hyros”), a leading multi-channel attribution company, today announced that AdTech Veteran Inman Breaux has been named Chief Executive Officer (CEO).

Key Points: 
  • Hyros Inc. (“Hyros”), a leading multi-channel attribution company, today announced that AdTech Veteran Inman Breaux has been named Chief Executive Officer (CEO).
  • View the full release here: https://www.businesswire.com/news/home/20230328005272/en/
    Hyros Announces AdTech Veteran & Entrepreneur Inman Breaux as Chief Executive Officer to Helm the Leading Multi-Channel Attribution Company (Photo: Business Wire)
    Alex Becker, founder of Hyros, has transitioned from his role as CEO and has assumed the position of Chief Revenue Officer and will be heavily focused on product development.
  • “Inman’s years of experience, deep industry connections and leadership voice that has helped shape the AdTech industry is a tremendous asset to help drive Hyros forward.
  • Hyros provides the highest level of ad tracking for digital businesses leading to significant return on ROI.

5AM Ventures Celebrates 20th FDA Product Approval Investing in Breakthrough Science

Retrieved on: 
Thursday, March 23, 2023
Cancer, Partner (business rank), CDTX, Fungemia, Science, VII, Patient, Investment, SAN, Addiction, FDA, Therapy, Regulation of tobacco by the U.S. Food and Drug Administration, Food, Pharmaceutical industry, Cryptocurrency

REZZAYO is the first new treatment option approved for patients with candidemia and invasive candidiasis in over a decade.

Key Points: 
  • REZZAYO is the first new treatment option approved for patients with candidemia and invasive candidiasis in over a decade.
  • REZZAYO was developed by Cidara Therapeutics, Inc. (Nasdaq: CDTX), a company seeded and then supported by 5AM Ventures through its Series A and Series B rounds.
  • 5AM’s Scott Rocklage served as chair of the board of directors from the company’s inception in 2012 through 2019.
  • “Success for 5AM Ventures is achieved when we make a difference in patients’ lives,” said Andrew Schwab, Managing Partner.

Abeona Therapeutics Announces Acceptance of Abstract on EB-101 Phase 3 VIITAL™ Study Results for Oral Presentation at International Societies for Investigative Dermatology (ISID) 2023 Meeting

Retrieved on: 
Thursday, March 16, 2023
Stanford University School of Medicine, Concha bullosa, Principal, International Society for NeuroVirology, VII, Safety, ISID, RDEB, Pharmaceutical industry, Veterinary medicine, Dermatology

NEW YORK and CLEVELAND, March 16, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that additional data from its pivotal Phase 3 VIITAL™ study of EB-101 for recessive dystrophic epidermolysis bullosa (RDEB) has been accepted for an oral presentation at the inaugural International Societies for Investigative Dermatology (ISID) Meeting, being held May 10-13, 2023 in Tokyo, Japan.

Key Points: 
  • NEW YORK and CLEVELAND, March 16, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that additional data from its pivotal Phase 3 VIITAL™ study of EB-101 for recessive dystrophic epidermolysis bullosa (RDEB) has been accepted for an oral presentation at the inaugural International Societies for Investigative Dermatology (ISID) Meeting, being held May 10-13, 2023 in Tokyo, Japan.
  • Abeona previously reported positive top-line efficacy and safety data from the VIITAL study in November 2022.
  • Abstract number 806 entitled, “Results from VIITAL: A phase 3, randomized, intrapatient-controlled trial of an investigational collagen type VII gene–corrected autologous cell therapy, EB-101, for the treatment of recessive dystrophic epidermolysis bullosa (RDEB),” will be presented by Jean Tang, M.D., Ph.D., Professor of Dermatology, Stanford University School of Medicine and Principal Investigator of the VIITAL study during a session between 1:15-3:45 p.m. Japan Standard Time on May 11, 2023.